Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New York AG’s Inquiry Into Pharmaceutical Trading Practices Continues Following Cardinal Settlement

This article was originally published in The Pink Sheet Daily

Executive Summary

As part of the agreement, the firm is required to enter “Wholesaler Safe Product Practice” agreement.

You may also be interested in...



AmerisourceBergen To Purchase All Drugs Directly From Manufacturers

The wholesaler currently buys less than 0.5% of U.S-distributed drugs from the secondary wholesale market.

N.Y. Attorney General Seeks Information On Wholesaler Deals With Secondary Market

Pharmaceutical wholesalers including Cardinal, ABC are subpoenaed by AG Eliot Spitzer's office in an inquiry into the wholesale secondary market, which has been associated with counterfeiting. The three top wholesalers have previously stated their intentions to cut back on secondary purchases.

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.

Topics

UsernamePublicRestriction

Register

PS063605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel